SYRE Spyre Therapeutics, Inc.
FY2025 10-K
Spyre Therapeutics, Inc. (SYRE) filed its fiscal year 2025 10-K annual report with the SEC on Feb 19, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model redesigned as clinical stage biotech focused on next-generation monoclonal antibodies for IBD and immune-mediated diseases
- • Emphasis on half-life extended antibodies aiming for less frequent, self-administered subcutaneous injections
Management Discussion & Analysis
- • No revenue reported in FY 2026, focus on pre-clinical stage asset acquisition and licensing
- • No profitability or margin data provided due to early-stage operations and recent acquisitions
Risk Factors
- • Legal risk from increased costs to comply with Nasdaq listing rules and SEC requirements post going public
- • Macroeconomic impact of $2.0M lease termination fee for Austin office abandonment creating liquidity pressure
Financial SummaryXBRL
Revenue
$0
Net Income
-$155M
ROE
-21.7%
Total Assets
$778M
Operating Cash Flow
-$169M
Source: XBRL data from Spyre Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Spyre Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.